ActoGeniX NV, of Ghent, Belgium, appointed Pol Bamelis to its board.
Affectis Pharmaceuticals AG, of Munich, Germany, appointed Jesper Wiklund chief business officer and head of finance. Also, Joachim Rothe took over as chairman of the company's supervisory board and Domenico Valerio was appointed vice chairman, while Alex Martin was added to the board.
Aldagen Inc., of Durham, N.C., appointed Martin Murphy Jr. to its board.
Amgen Inc., of Thousand Oaks, Calif., named David Lacey senior vice president, head of research.
Anesiva Inc., of South San Francisco, named Yvonne Richardson vice president of manufacturing and Shaun Comfort director of clinical research.
Biopartners Holdings AG, of Baar, Switzerland, promoted Conrad Savoy to chief scientific officer.
BrainCells Inc., of San Diego, named Seth Goldblum vice president, business development.
CellCyte Genetics Corp., of Kirkland, Wash., appointed Mark Reys vice president of operations and Mark Hollywood director of quality assurance and quality control.
Chroma Therapeutics Ltd., of Oxford, UK, appointed Klaus Veitinger as a nonexecutive director.
Conatus Pharmaceuticals Inc., of San Diego, elected Harold Van Wart to its board.
CytRx Corp., of Los Angeles, named Shi Chung Ng senior vice president of research and development.
Exelixis Inc., of South San Francisco, appointed Arthur DeCillis vice president, clinical research, and Anne Champsaur vice president, drug safety.
Galenea Corp., of Cambridge, Mass., appointed Mark Benjamin president and CEO.
GPC Biotech AG, of Martinsried, Germany, elected Donald Soltysiak to its supervisory board.
Hana Biosciences Inc., of South San Francisco, promoted Hana Moran to vice president, regulatory affairs and quality assurance.
InteKrin Therapeutics Inc., of Los Altos, Calif., appointed Linda Slanec Higgins vice president, preclinical research and development.
IntelGenx Technologies Corp., of St. Laurent, Quebec, appointed Taylor Hutchison chief financial officer.
Intercept Pharmaceuticals Inc., of New York, named Alex Martin to the new position of chief operating officer.
Intradigm Corp., of Palo Alto, Calif., appointed Samuel Zalipsky vice president, technology development.
MediGene AG, of Martinsried, Germany, appointed Thomas Klaue chief financial officer.
Symphogen A/S, of Copenhagen, Denmark, said Ian Nicholson joined its board.
Synosia Therapeutics, of South San Francisco, appointed Stephen Bandak chief medical officer.
Upstream Biosciences Inc., of Vancouver, British Columbia, appointed Edward Kiruluta to its scientific advisory board.
Xechem International Inc., of New Brunswick, N.J., added Robert Swift to its board.